



A novel mutation in the transmembrane 6 domain of GABBR2 leads to a Rett-like phenotype

Marie-Laure Vuillaume, Mederic Jeanne, Li Xue, Sophie Blesson, Anne-Sophie Denomme-Pichon, Servane Alirol, Celine Brulard, Estelle Colin, Bertrand Isidor, Brigitte Gilbert-Dussardier, et al.

► To cite this version:

Marie-Laure Vuillaume, Mederic Jeanne, Li Xue, Sophie Blesson, Anne-Sophie Denomme-Pichon, et al.. A novel mutation in the transmembrane 6 domain of GABBR2 leads to a Rett-like phenotype. *Annals of Neurology*, 2018, 83 (2), pp.437-439. 10.1002/ana.25155 . hal-01730199

HAL Id: hal-01730199

<https://univ-rennes.hal.science/hal-01730199>

Submitted on 13 Dec 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A novel mutation in the TM6 domain of GABBR2 leads to a Rett-like phenotype

Vuillaume ML^{1,2}, Jeanne M^{1,2}, Xue L³, Blesson S¹, Denommé-Pichon AS^{4,5}, Alirol S², Brulard C^{2,6}, Colin E^{4,5}, Isidor B^{7,8}, Gilbert-Dussardier B^{9,10}, Odent S^{11,12}, Parent P¹³, Donnart A¹⁴, Redon R¹⁴, Bézieau S^{7,15}, Rondard P³, Laumonnier F^{1,2}, Toutain A^{1,2}

1 Service de Génétique, Centre Hospitalier Universitaire, Tours, France

2 UMR INSERM 930, Faculté de Médecine, Université François-Rabelais, Tours, France

3 Institut de Génomique Fonctionnelle (IGF), CNRS UMR5203 - INSERM U1191- Université de Montpellier, Montpellier, France

4 Service de Génétique, Centre Hospitalier Universitaire, Angers, France

5 UMR INSERM 1083 - CNRS 6015, Faculté de Médecine, Université d'Angers, Angers, France

6 Plateforme Biologie Moléculaire des Cancers, Centre Hospitalier Universitaire, Tours, France

7 Service de Génétique, Centre Hospitalier Universitaire, Nantes, France

8 INSERM, UMR-S 1238, Université de Nantes, Nantes, France

9 Service de Génétique, Centre Hospitalier Universitaire, Poitiers, France

10 EA 3808, Université de Poitiers

11 Service de Génétique Clinique, Centre Hospitalier Universitaire, Rennes, France

12 CNRS UMR 6290 IGDR, Faculté de médecine, Université de Rennes 1, Rennes

13 Génétique médicale, Centre Hospitalier Universitaire, Brest, France

14 INSERM, CNRS, Université de Nantes, Centre Hospitalier Universitaire, l'Institut du thorax, Nantes, France

15 CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.

Corresponding author: Pr Annick Toutain, Service de Génétique, Centre Hospitalier Universitaire, 2 Boulevard Tonnellé, 37044 Tours cedex 9, France. Tel.: +33247478850; Fax: +33247478653; Email: annick.toutain@univ-tours.fr

Running head: A novel GABBR2 mutation in the TM6 domain

Dear Editor,

We read with great interest the recent article published by Yoo et al.¹ reporting four additional RETT-like (RTT) patients with the recurring A567T *GABBR2* mutation². More interestingly, they showed, with *in vitro* and *in vivo* functional studies, that the severity of the phenotype caused by *GABBR2* mutations was directly linked to their impact on GABA signaling activity, this latter being more reduced with the two missense mutations, S695I and I705N associated with epileptic encephalopathy (EE)^{1,3}. They hypothesized that variants position in different transmembrane (TM) domains of *GABBR2*, TM6 for S695I and I705N, and TM3 for A567T, could determine the phenotypic expression. This hypothesis was recently reinforced with the report of a novel *GABBR2* mutation also in TM6 and associated with infantile epileptic spasms⁴.

We present a novel *de novo* heterozygous *GABBR2* mutation, A707T (Fig 1 A), identified by Whole Exome Sequencing also located in TM6 of *GABBR2* (Fig 1B) but associated with a RTT phenotype. The carrier, a 12 year-old girl, had profound intellectual disability, hand stereotypies, sleep and breathing disturbances but no history of seizures. This mutation, predicted pathogenic by *in silico* analyses, lies in a region crucial for GPCR activation and positive allosteric modulation⁵. To assess its impact on GABA signaling activity, we co-expressed the two GABA_B subunits with the chimeric G-protein G α q_{i9} in HEK-293 cells and measured the accumulation of inositol phosphate (IP-1) induced by the ligand GABA. We showed that the signaling activity of our A707T mutant is weakly induced by the agonist compared to that of the wild-type (Fig 1C), and this without altering *GABBR2* cell surface expression (Fig 1D). The same results were observed with the A567T and I705N mutants (Fig 1C). Moreover, the four mutants tested have a basal activity stronger than that of the wild-type which might explain why the mutated receptor cannot be stimulated efficiently by

GABA (Fig 1C,1E). This basal activity is reversed by the competitive antagonist CGP54626, except for the mutant S695I which is already fully active in the absence of GABA and do not respond to GABA (Fig 1C, E) in accordance with Yoo et al. data¹. To conclude, our results show that *GABBR2* mutations located within TM6 can also be associated with a Rett-like phenotype. The novel mutation described here, A707T, also exerts a deleterious effect on GABAB receptor activity. This deleterious effect could result from a constitutive activity of the mutated GABA_B receptor highlighting a novel putative pathogenic mechanism for *GABBR2* variants.

Acknowledgement

This work was supported by grants from the French Ministry of Health and Health Regional Agency from Poitou-Charentes (HUGODIMS, 2013, RC14_0107). The funder has no role in study design, data collection, analysis, interpretation of the data, writing of the report and the decision to submit the paper for publication. We thank Dr. Xavier Rovira (University of Vic, Spain) for the structural model of the human GABAB2 7TM. The inositol-phosphate experiments have been performed using the ARPEGE (Pharmacology Screening-Interactome) platform facility at the Institut de Génomique Fonctionnelle (Montpellier, France).

Author Contributions

MLV, MJ, LX, PR, FL and AT contributed to the conception and design of the study. MLV, MJ, LX, SB, ASD, SA, CB, AD, RR, SB, PR, FL and AT contributed to the acquisition and analysis of data. All authors contributed equally to drafting the text and preparing the figures.

Potential Conflicts of Interest

Nothing to report.

References

1. Yoo Y, Jung J, Lee YN, et al. GABBR2 mutations determine phenotype in rett syndrome and epileptic encephalopathy. *Ann Neurol* 2017;82:466-478
2. Lopes F, Barbosa M, Ameur A, et al. Identification of novel genetic causes of Rett syndrome-like phenotypes. *J Med Genet* 2016;53:190-199
3. EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome Project, Epi4K Consortium. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. *Am J Hum Genet* 2014;95:360-370
4. Hamdan FF, Myers CT, Cossette P, et al. High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies. *Am J Hum Genet* 2017;101:664-685
5. Dupuis DS, Relkovic D, Lhuillier L, et al. Point mutations in the transmembrane region of GABAB2 facilitate activation by the positive modulator N,N'-dicyclopentyl-2-methylsulfany 5-nitro-pyrimidine-4,6-diamine (GS39783) in the absence of the GABAB1 subunit. *Mol Pharmacol* 2006;70:2027-2036

Figure legend

Figure 1: Identification and functional analysis of the A707T mutation

A) Sanger sequencing electrophoregrams showing the *GABBR2* heterozygous missense mutation c.2119G>A, p.(Ala707Thr) in the proband and wild-type sequences in her parents and amino-acid alignments showing high conservation of the residue 707 across multiple species. TM: Transmembrane domain.

B-E) Functional analysis of the GABA_B receptor mutants. B) Structural model of the human GABA_{B2} heptahelical transmembrane domain (7TM) with the mutated residues in RTT and EE patients indicated in Corey–Pauling–Koltun representation. All the amino acid residues affected by the human mutations are in transmembrane (TM) domains 3 and 6. C) Inositol-phosphate accumulation mediated by the wild-type and mutant Flag-tagged GABA_{B2} co-expressed with the wild-type GABA_{B1a} and the chimeric G protein subunit Gαq_{i9} (a Gαq protein in which the last nine C-terminal residues have been replaced by those from Gαi₂) which facilitates the coupling of Gi-coupled receptors to the phospholipase C signaling pathway (Monnier et al, 2011). Data are means ± SEM of at least three independent experiments. D) Cell surface levels of the Flag-tagged GABA_{B2} mutants when co-expressed with the wild-type GABA_{B1a}. Amounts of Flag-tagged GABA_{B2} mutants at the cell surface were quantified by ELISA in intact (i.e. non-permeabilized) cells using the Flag epitope at the extracellular N-terminus of the GABA_{B2} subunit. Data are expressed as means ± SEM of triplicates from a typical experiment repeated at least three times. E) Inositol-phosphate accumulation mediated by the wild-type and mutant Flag-tagged GABA_{B2} co-expressed with the wild-type GABA_{B1a} and Gαq_{i9}, as in panel B. The GABA_B receptor wild-type and GABA_B mutants were incubated with 100 μM GABA, 10 μM CGP54626 or both. Data are means ± SEM of at least three independent experiments.

Monnier C., Tu H., Bourrier E., et al. (2011) Transactivation between two 7-TM domains:
implication heterodimeric GABAB receptor activation. EMBO J. 30, 32-42.




Figure 1: Identification and functional analysis of the A707T mutation

A) Sanger sequencing electrophoregrams showing the GABBR2 heterozygous missense mutation c.2119G>A, p.(Ala707Thr) in the proband and wild-type sequences in her parents and amino-acid alignments showing high conservation of the residue 707 across multiple species. TM: Transmembrane domain.

B-E) Functional analysis of the GABAB receptor mutants. B) Structural model of the human GABAB2 heptahelical transmembrane domain (7TM) with the mutated residues in RTT and EE patients indicated in Corey–Pauling–Koltun representation. All the amino acid residues affected by the human mutations are in transmembrane (TM) domains 3 and 6. C) Inositol-phosphate accumulation mediated by the wild-type and mutant Flag-tagged GABAB2 co-expressed with the wild-type GABAB1a and the chimeric G protein subunit Gq α 9 (a G α q protein in which the last nine C-terminal residues have been replaced by those from G α i2) which facilitates the coupling of Gi-coupled receptors to the phospholipase C signaling pathway (Monnier et al, 2011). Data are means \pm SEM of at least three independent experiments. D) Cell surface levels of the

Flag-tagged GABAB2 mutants when co-expressed with the wild-type GABAB1a. Amounts of Flag-tagged GABAB2 mutants at the cell surface were quantified by ELISA in intact (i.e. non-permeabilized) cells using the Flag epitope at the extracellular N-terminus of the GABAB2 subunit. Data are expressed as means \pm

SEM of triplicates from a typical experiment repeated at least three times. E) Inositol-phosphate accumulation mediated by the wild-type and mutant Flag-tagged GABAB2 co-expressed with the wild-type GABAB1a and Ggqi9, as in panel B. The GABAB receptor wild-type and GABAB mutants were incubated with 100 μ M GABA, 10 μ M CGP54626 or both. Data are means \pm SEM of at least three independent experiments.

Monnier C., Tu H., Bourrier E., et al. (2011) Transactivation between two 7-TM domains: implication heterodimeric GABAB receptor activation. *EMBO J.* 30, 32-42.

254x338mm (300 x 300 DPI)